Antipsychotic-Induced Neurological Adverse Events
https://doi.org/10.30629/2618-6667-2019-17-3-75-86
Abstract
Aim of study: analyze recent publications, related to the incidence, clinical signs and treatment of antipsychotic-induced movement disorders.
Material and methods: articles published in the last 10 years were searched in Scopus, Pubmed and Cochrane Library using following keywords: neurological side-effects, dyskinesia, antipsychotics.
Results: current review summarizes the data on epidemiology, diagnosis, and treatment of neurological complications of antipsychotics were found. Provides information on risk factors and clinical features of parkinsonism, dystonia and tardive dyskinesia, as well as possible treatment options.
Conclusion: early differential diagnosis of neurological complications and taking into account risk factors will reduce frequency and increase compliance.
About the Authors
N. S. Cherkasov
FSBSI Mental Health Research Centre
Russian Federation
Russian Federation
Nikita S. Cherkasov - Clinical Resident.
MoscowV. S. Sheshenin
FSBSI Mental Health Research Centre
Russian Federation
Russian Federation
Vladimir S. Sheshenin - PhD, MD, Cand. of Sci. (Med.), Leading Researcher.
MoscowM. A. Savina
FSBSI Mental Health Research Centre
Russian Federation
Russian Federation
Maria A. Savina - PhD, MD, Dr. of Sci. (Med.), Leading Researcher.
MoscowReferences
1. Schonecker M. Paroxysmal dyskinesia as the effect of megaphen. Nervenarzt. 1957;28(12):550-553. http://www.ncbi.nlm.nih.gov/pubmed/13517450.
2. Faurbye A, Rasch P-J, Petersen PB, et al. Neurological Symptoms in Pharmagotherapy of Psychoses. Acta Psychiatr. Scand. 1964;40(1):10-27. https://doi.org/10.1111/j.1600-0447.1964.tb05731.x.
3. Woerner MG, Alvir JM, Saltz BL, et al. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am. J. Psychiatry. 1998;155(11):1521— 1528. https://doi.org/10.1176/ajp.155.11.1521.
4. Glazer WM, Morgenstern H, Doucette JT. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J. Clin. Psychiatry. 1993;54(4):133-139. http://www.ncbi.nlm.nih.gov/pubmed/8098030.
5. Chakos MH, Alvir JMJ, Woerner MG, et al. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Arch. Gen. Psychiatry. 1996;53(4):313—319. https://doi.org/10.1001/arch-psyc.1996.01830040049009.
6. Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr. Opin. Psychiatry. 2008;21(2):151-156. https://doi.org/10.1097/YCO.0b013e3282f531326.
7. Woods SW, Morgenstern H, Saksa JR, et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J. Clin. Psychiatry. 2010;71(4):463-474. https://doi.org/10.4088/JCP.07m03890yel.
8. Tenback DE, van Harten PN, Slooff CJ, van Os J. Incidence and persistence of tardive dyskinesia and extrapyramidal symptoms in schizophrenia. J. Psychopharmacol. 2010;24(7):1031-1035. https://doi.org/10.1177/0269881109106306.
9. de Leon J. The effect of atypical versus typical antipsychotics on tardive dyskinesia: a naturalistic study. Eur. Arch. Psychiatry Clin. Neurosci. 2007;257(3):169-172. https://doi.org/10.1007/s00406-006-0705-z.
10. Woerner MG, Correll CU, Alvir JMJ, et al. Incidence of Tardive Dyskinesia with Risperidone or Olanzapine in the Elderly: Results from a 2-Year, Prospective Study in Antipsychotic-Naive Patients. Neuropsychopharmacology. 2011;36(8):1738-1746. https://doi.org/10.1038/npp.2011.55.
11. Youssef HA, Waddington JL. Morbidity and mortality in tardive dyskinesia: associations in chronic schizophrenia. Acta Psychiatr. Scand. 1987;75(1):74-77. https://doi.org/10.1111/]'.1600-0447.1987.tb02754.x.
12. Ballesteros J, Gonzalez-Pinto A, Bulbena A. Tardive dyskinesia associated with higher mortality in psychiatric patients: Results of a metaanalysis of seven independent studies. J. Clin. Psychopharmacol. 2000;20(2):188-194. https://doi.org/10.1097/00004714-200004000-00011.
13. Skidmore F, Reich SG. Tardive dystonia. Current Treatment Options in Neurology. 2005;7(3):231-236. D0I:10.1007/s11940-005-0016-0.
14. Solmi M, Pigato G, Kane JM, Correll CU. Clinical risk factors for the development of tardive dyskinesia. J. Neurol. Sci. 2018;389:21-27. https://doi.org/10.1016/j.jns.2018.02.012.
15. Jr HK, Ilahi MM, Shenker D. Theoretical Implications of the Use of L-Dopa in Parkinsonism. Acta Neurol. Scand. 1970;46(4-5):409-441. https://doi.org/10.1111/].1600-0404.1970.tb05804.x.
16. Z. L, X.L. S. Etiological characteristics and treatment of tardive dyskinesia. Neural Regen. Res. 2006;1(6):549-552. http://ovidsp.ovid.com/ovid-web.cgi?T=JS&PAGE=reference&D=emed10&NEWS=N&AN=351606435.
17. Vaddadi K, Hakansson K, Clifford J, Waddington J. Tardive dyskinesia and essential fatty acids. Int. Rev. Psychiatry. 2006;18(2):133-143. https://doi.org/10.1080/09540260600583114.
18. Lohr JB, Kuczenski R, Niculescu AB. Oxidative mechanisms and tardive dyskinesia. CNS Drugs. 2003;17(1):47-62. https://doi.org/10.2165/00023210-200317010-00004.
19. Elkashef AM, Wyatt RJ. Tardive dyskinesia: Possible involvement of free radicals and treatment with vitamin E. Schizophr. Bull. 1999;25(4):731-740. https://doi.org/10.1093/oxfordjournals.schbul.a033414.
20. Bishnoi M, Chopra K, Kulkarni SK. Possible anti-oxidant and neuroprotective mechanisms of zolpidem in attenuating typical anti-psychotic-induced orofacial dyskinesia-A biochemical and neurochemical study. Prog. Neuro-Psychopharmacology Biol. Psychiatry. 2007;31(5):1130-1138. https://doi.org/10.1016/].pnpbp.2007.04.007.
21. Gunne LM, Andren PE. An Animal Model for Coexisting Tardive Dyskinesia and Tardive Parkinsonism. Clin. Neuropharmacol. 1993;16(1):90-95. https://doi.org/10.1097/00002826-199302000-00012.
22. Kulkari SK, Naidu PS. Pathophysiology and drug therapy of tardive dyskinesia: Current concepts and future perspectives. Drugs of Today. 2003;39(1):19-49. https://doi.org/10.1358/dot.2003.39.1.799430.
23. Levin OS. Lekarstvennye diskinezii. Sovremennaya terapiya v psikhiatrii i nevrologii. 2014;3:4-13. (In Russ.).
24. Mendhekar DN, Duggal HS. Clozapine-induced tardive dyskinesia and hypothyroidism. J Neuropsychiatry Clin. Neurosci. 2006;18(2):245-246. https://doi.org/10.1176/]np.2006.18.2.245.
25. Duggal HS, Mendhekar DN. Clozapine-induced tardive dystonia (blepharospasm). J. Neuropsychiatry Clin. Neurosci. 2007;19(1):86-87. https://doi.org/10.1176/]np.2007.19.1.86.
26. Molho ES, Factor SA. Possible tardive dystonia resulting from clozapine therapy. Mov. Disord. 1999;14(5):873-874. https://doi.org/10.1002/1531-8257(199909)14:5<873::AID-MDS1027>3.0.C0;2-U.
27. Frei K, Truong DD, Fahn S, et al.The nosology of tardive syndromes. J. Neurol. Sci. 2018;389:10-16. https://doi.org/10.1016/j.jns.2018.02.008.
28. Tiganov AS, Snezhnevskii AV, Orlovskaya DD. Rukovodstvo po psikhiatrii. V 2 tomakh. Tom 1. Pod red. Tiganova AS. Moskva: Meditsina; 2012. (In Russ.).
29. Ryu S, Yoo JH, Kim JH, et al. Tardive Dyskinesia and Tardive Dystonia With Second-Generation Antipsychotics in Non-Elderly Schizophrenic Patients Unexposed to First-Generation Antipsychotics. J. Clin. Psychopharmacol. 2015;35(1):13-21. https://doi.org/10.1097/JCP.0000000000000250.
30. Federal'nye klinicheskie rekomendatsii po diagno-stike i lecheniyu shizofrenii. Rossiiskoe Obshchestvo Psikhiatrov. 2013. (In Russ.). Available at:https://goo.su/0DAl(Accessed 16.09.18).
31. Bergman H, Soares-Weiser K. Anticholinergic medication for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2018;(1). https://doi.org/10.1002/14651858.CD000204.pub2.
32. Pappa S, Tsouli S, Apostolou G, et al. Effects of amantadine on tardive dyskinesia: A randomized, double-blind, placebo-controlled study. Clin. Neuropharmacol. 2010;33(6):271-275. https://doi.org/10.1097/WNF.0b013e3181ffde32.
33. Vetokhina TN, Fedorova NV, Voronina EF. Clinical manifestations and course of neuroleptic tardive dyskinesia. Psychiatry. 2006;3(21):47-54. (In Russ.).
34. Vestal RE, Kornhauser DM, Hollifield JW, Shand DG. Inhibition of propranolol metabolism by chlorpromazine. Clin. Pharmacol. Ther. 1979;25(1):19-24. https://doi.org/10.1002/cpt197925119.
35. Silver JM, Yudofsky SC, Kogan M, Katz BL. Elevation of thioridazine plasma levels by propranolol. Am. J. Psychiatry. 1986;143(10):1290-1292. https://doi.org/10.1176/ajp.143.10.1290.
36. Garc ia-Santos G, Herrera F, Mart in V, et al. Antioxidant activity and neuroprotective effects of zolpidem and several synthesis intermediates. Free Radic. Res. 2004;38(12):1289-1299. https://doi.org/10.1080/10715760400017343.
37. Bishnoi M, Chopra K, KuLkarni SK. Possible anti-oxidant and neuroprotective mechanisms of zolpidem in attenuating typical anti-psychotic-induced orofacial dyskinesia — A biochemical and neurochemical study. Prog. Neuro-Psychopharmacology Biol. Psychiatry. 2007;31(5):1130-1138. https://doi.org/10.1016/]'.pnpbp.2007.04.007.
38. Alabed S, Latifeh Y, Mohammad HA, Bergman H. Gamma-aminobutyric acid agonists for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2018;4:CD000203. https://doi.org/10.1002/14651858.CD000203.pub4.
39. Richardson MA, Bevans ML, Weber JB, et al. Branched chain amino acids decrease tardive dyskinesia symptoms. Psychopharmacology (Berl). 1999;143(4):358-364. https://doi.org/10.1007/s002130050959.
40. Richardson MA, Small AM, Read LL, et al. Branched chain amino acid treatment of tardive dyskinesia in children and adolescents. J. Clin. Psychiatry. 2004;65(1):92-96. https://doi.org/10.4088/JCP.v65n0116.
41. Richardson MA, Bevans ML, Read LL, et al. Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men. Am. J. Psychiatry. 2003;160(6):1117-1124. https://doi.org/10.1176/appi.a]p.160.6.1117.
42. Waln O, Jankovic J. An Update on Tardive Dyskinesia: From Phenomenology to Treatment. Tremor and Other Hyperkinetic Movements 2013;3:1-11. https://doi: 10.7916/D88P5Z71.
43. Vijayakumar D, Jankovic J. Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia. Drugs. 2016;76(7):759-777. https://doi.org/10.1007/s40265-016-0566-3.
44. Zhang L, Chopp M, Meier DH, et al. Sonic hedgehog signaling pathway mediates cerebrolysin-improved neurological function after stroke. Stroke. 2013;44(7):1965-1972. https://doi.org/10.1161/STROKEAHA.111.000831.
45. Zhang C, Chopp M, Cui Y, et al. Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke. J. Neurosci. Res. 2010;88(15):3275-3281. https://doi.org/10.1002/jnr.22495.
46. Kontsevoi VA, Medvedev AV, Andrusenko MP et al. Use of cerebrolysin in the treatment of prolonged extrapyramidal complications of neuroleptic therapy. Zhurnal nevrologii i psihiatrii imeniS.S. Korsakova. 1997;97(6):39-44. http://www.ncbi.nlm.nih.gov/pubmed/11517474. (In Russ.).
47. Malykh AG, Sadaie MR. Piracetam and piracetamlike drugs: from basic science to novel clinical applications to CNS disorders. Drugs. 2010;70(3):287-312. https://doi.org/10.2165/11319230-000000000-00000.
48. Libov I, Miodownik C, Bersudsky Y, et al. Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: A randomized, doubleblind, placebo-controlled crossover study. J. Clin. Psychiatry. 2007;68(7):1031-1037. https://doi.org/10.4088/JCP.v68n0709.
49. Miyaoka T, Furuya M, Yasuda H, et al. Yi-gan san for the treatment of neuroleptic-induced tardive dyskinesia: an open-label study. Prog. Neuropsychopharmacol Biol. Psychiatry. 2008;32(3):761-764. https://doi.org/10.1016/j.pnpbp.2007.12.003.
50. Doo A-R, Kim S-N, Park J-Y, et al. Neuroprotective effects of an herbal medicine, Yi-Gan San on MPP+/ MPTP-induced cytotoxicity in vitro and in vivo. J. Ethnopharmacol. 2010;131(2):433-442. https://doi.org/10.1016/j.jep.2010.07.008.
51. Zhang W-F, Tan Y-L, Zhang X-Y, et al. Extract of Ginkgo biloba Treatment for Tardive Dyskinesia in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial. J. Clin. Psychiatry. 2010; 72(5):615-621. https://doi.org/10.4088/JCP.09m05125yel.
52. Viswanathan M, Siow YL, Paulose CS, Dakshinamurti K. Pineal indoleamine metabolism in pyridoxine-deficient rats. Brain Res. 1988;473(1):37-42. https://doi.org/10.1016/0006-8993(88)90312-5.
53. Lerner V, Miodownik C, Kaptsan A, et al. Vitamin B(6) in the treatment of tardive dyskinesia: a doubleblind, placebo-controlled, crossover study. Am. J. Psychiatry. 2001;158(9):1511-1514. https://doi.org/10.1176/appi.ajp.158.9.1511.
54. Guay DRP. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. Am. J. Geriatr. Pharmacother. 2010;8(4):331-373. https://doi.org/10.1016/].amjopharm.2010.08.006.
55. Rana AQ, Chaudry ZM, Blanchet PJ. New and emerging treatments for symptomatic tardive dyskinesia. Drug. Des. Devel. Ther. 2013;7:1329-1340. https://doi.org/10.2147/DDDT.S32328.
56. Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurotherapeutics. 2014;11(1):166-176. https://doi.org/10.1007/s13311-013-0222-5.
57. Hauser RA, Factor SA, Marder SR, et al. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia. Am. J. Psychiatry. 2017;174(5):476-484. https://doi.org/10.1176/appi.ajp.2017.16091037.
58. Citrome L. Deutetrabenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int. J. Clin. Pract. 2017;71(11):e13030. https://doi.org/10.1111/ijcp.13030.
Review
For citations:
Cherkasov N.S., Sheshenin V.S., Savina M.A. Antipsychotic-Induced Neurological Adverse Events. Psychiatry (Moscow) (Psikhiatriya). 2019;17(3):75-86. (In Russ.) https://doi.org/10.30629/2618-6667-2019-17-3-75-86
Views:
821
Email this article 
